Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Sep;16(5):391-5.

Efficacy of Tablet huperzine-A on Memory, Cognition, and Behavior in Alzheimer's Disease

Affiliations
  • PMID: 8701750
Free article
Clinical Trial

Efficacy of Tablet huperzine-A on Memory, Cognition, and Behavior in Alzheimer's Disease

S S Xu et al. Zhongguo Yao Li Xue Bao. .
Free article

Abstract

Aim: To evaluate the efficacy and safety of tablet huperzine-A (Hup) in patients with Alzheimer's disease.

Methods: Using multicenter, prospective, double-blind, parallel, placebo controlled and randomized method, 50 patients were administered orally 0.2 mg (4 tablets) Hup and 53 patients were given po 4 tablets of placebo bid for 8 wk. All patients were evaluated with Wechsler memory scale, Hasegawa dementia scale, mini-mental state examination scale, activity of daily living scale, treatment emergency symptom scale, and measured with BP, HR, ECG, EEG, ALT, AKP, BUN, Cr, Hb, WBC, and urine routine.

Results: About 58% (29/50) of patients treated with Hup showed improvements in their memory (P < 0.01), cognitive (P < 0.01), and behavioral (P < 0.01 functions. The efficacy of Hup was better than placebo (36%, 19/53) (P < 0.05). No severe side effect was found.

Conclusion: Hup is a promising drug for symptomatic treatment of Alzheimer's disease.

Similar articles

See all similar articles

Cited by 28 articles

See all "Cited by" articles

LinkOut - more resources

Feedback